An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
暂无分享,去创建一个
Bingshu E. Chen | H. Eich | V. Diehl | J. Connors | J. Winter | B. Dörken | S. Horning | R. Pearcey | M. Gospodarowicz | M. Crump | L. Shepherd | P. Borchmann | A. Engert | A. Lohri | M. Fuchs | R. Meyer | B. Klimm | B. E. Chen | A. Hay | J. Marková | H. Goergen | R. Meyer | Volker Diehl | B. Chen | V. Diehl | B. Dörken
[1] A. Merla,et al. Targeted Therapy in Biliary Tract Cancers , 2015, Current Treatment Options in Oncology.
[2] M. Federico,et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] D. Sawyer. Anthracyclines and heart failure. , 2013, The New England journal of medicine.
[4] R. Küppers,et al. Hodgkin lymphoma. , 2012, The Journal of clinical investigation.
[5] R. Hoppe,et al. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. , 2012, Blood.
[6] J. Raemaekers,et al. Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma , 2012 .
[7] J. Radford,et al. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial , 2012 .
[8] H. Eich,et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] J. Lindebjerg,et al. Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Pignon,et al. Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO). , 2012 .
[11] Itzhak Avital,et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.
[12] Bingshu E. Chen,et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. , 2012, The New England journal of medicine.
[13] R. Hehlmann,et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia , 2011, Leukemia.
[14] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Greil,et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Harari,et al. Understanding resistance to EGFR inhibitors—impact on future treatment strategies , 2010, Nature Reviews Clinical Oncology.
[17] R. Greil,et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.
[18] A. Zhu,et al. Genetics of biliary tract cancers and emerging targeted therapies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Zuofeng Li,et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. , 2009, International journal of radiation oncology, biology, physics.
[20] S. Hirohashi,et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma , 2007, British Journal of Cancer.
[21] D. Haller,et al. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer , 2007, Cancer.
[22] M. Ducreux,et al. Cetuximab plus Gemcitabine-Oxaliplatin (GEMOX) in Patients with Refractory Advanced Intrahepatic Cholangiocarcinomas , 2007, Oncology.
[23] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Takaoka,et al. Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.
[25] P. Philip,et al. Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Noordijk,et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[27] D. Lefkopoulos,et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? , 2005, International journal of radiation oncology, biology, physics.
[28] V. Diehl,et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Connors,et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Bonadonna,et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[32] C. Boland,et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers , 2002, Oncogene.
[33] T. Itoi,et al. K‐ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers , 1999, Pathology international.
[34] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.